Enzyme Replacement Therapy (ERT): How It Works, Which Diseases It Treats, Costs, and What to Expect

For people living with rare lysosomal storage diseases — conditions where the body cannot produce a specific enzyme needed to break down cellular waste — enzyme replacement therapy represents one of the most significant medical advances of the past three decades. Before ERT became available, many of these conditions had no effective treatment and caused progressive, often fatal organ damage.

This guide explains what ERT is, the science behind how it works, which diseases are currently treated with FDA-approved ERT drugs, what the infusion experience involves, how much it costs in the United States, how insurance coverage works, and what the current limitations and future directions of ERT research look like.

What Are Lysosomal Storage Diseases?

To understand why ERT is needed, it helps to first understand the conditions it treats. Lysosomal storage diseases (LSDs) are a group of approximately 50 rare inherited metabolic disorders caused by genetic mutations that result in the deficiency or complete absence of a specific lysosomal enzyme.

Lysosomes are small compartments inside cells that act as the cell’s recycling and waste disposal system. They contain dozens of enzymes that break down complex molecules — fats, proteins, carbohydrates, and cellular debris — into simpler components that can be reused or excreted. When a specific enzyme is missing or non-functional, the substrates that enzyme would normally break down accumulate inside the lysosome and eventually throughout the cell, causing progressive cell damage and organ dysfunction.

Individually, each LSD is rare — most affect fewer than 1 in 50,000 people. But collectively, LSDs affect approximately 1 in 5,000 live births worldwide, making them an important category of rare disease. They are typically diagnosed in childhood, though some milder forms are not identified until adulthood.

What Is Enzyme Replacement Therapy?

Enzyme Replacement Therapy (ERT) is a medical treatment that delivers laboratory-manufactured versions of the missing or deficient enzyme directly into the patient’s bloodstream through intravenous infusion. The manufactured enzyme is produced using recombinant DNA technology — human enzyme genes are inserted into host cells (typically Chinese hamster ovary cells or human cell lines), which then produce large quantities of the functional enzyme that can be purified and administered to patients.

Once infused, the replacement enzyme circulates in the bloodstream and is taken up by cells throughout the body. Inside the cell, it travels to the lysosome and begins breaking down the accumulated substrate — the same job the patient’s own deficient enzyme should have been doing. This reduces the toxic buildup, relieves symptoms, slows disease progression, and in many cases significantly improves organ function.

ERT does not correct the underlying genetic mutation — it is not a cure. Patients must receive infusions on an ongoing basis, typically every one to two weeks for the rest of their lives, to maintain the therapeutic effect.

How ERT Is Administered — The Infusion Experience

Understanding what ERT treatment actually involves helps patients and families prepare for the commitment it requires, along with understanding blood collection tubes used in diagnostic testing.

1. Infusion setting: ERT is administered intravenously — through a needle or port into a vein. Infusions are typically given at a hospital infusion center, a specialized rare disease clinic, or in some cases at home with a trained nurse for patients who have tolerated treatment well over time.
2. Duration: A single infusion session typically lasts 1 to 4 hours depending on the specific ERT drug, the dose (calculated by body weight), and the patient’s infusion rate tolerance. First infusions are given slowly and monitored carefully; experienced patients may have their infusion rate gradually increased over time.
3. Frequency: Most ERT protocols require infusions every two weeks. Some conditions (such as Fabry disease) may use biweekly or monthly schedules depending on the specific drug used.
4. Pre-medication: Many patients receive antihistamines, acetaminophen, or corticosteroids before infusion to reduce the risk of infusion-related reactions. This is standard practice, especially in the early months of treatment.
5. Monitoring: Vital signs — blood pressure, heart rate, oxygen saturation, and temperature — are monitored before, during, and after the infusion. Nursing staff are present throughout the session to detect and manage any reactions.
6. Lifestyle impact: Most patients can resume normal activities the day after an infusion. Some experience fatigue or mild flu-like symptoms for 24–48 hours following treatment, particularly in the early months. Many patients work, attend school, or travel normally between infusion sessions.

Diseases Treated With FDA-Approved ERT

The following lysosomal storage diseases currently have FDA-approved enzyme replacement therapies available in the United States:

Disease	Missing Enzyme	Organs Affected	FDA-Approved ERT Drug(s)	Approval Year
Gaucher Disease Type 1	Glucocerebrosidase	Spleen, liver, bones, blood	Imiglucerase (Cerezyme), Velaglucerase alfa (VPRIV), Taliglucerase alfa (Elelyso)	1994, 2010, 2012
Fabry Disease	Alpha-galactosidase A	Heart, kidneys, nervous system, skin	Agalsidase beta (Fabrazyme), Agalsidase alfa (Replagal)*	2003 (*EU only)
Pompe Disease	Acid alpha-glucosidase (GAA)	Muscles, heart, respiratory system	Alglucosidase alfa (Myozyme/Lumizyme), Avalglucosidase alfa (Nexviazyme)	2006, 2021
MPS I (Hurler/Scheie)	Alpha-L-iduronidase	Joints, liver, spleen, eyes, airways	Laronidase (Aldurazyme)	2003
MPS II (Hunter)	Iduronate-2-sulfatase	Joints, heart, lungs, liver	Idursulfase (Elaprase), Pabinafusp alfa (Izcargo)*	2006 (*Japan only)
MPS IVA (Morquio A)	Galactosamine-6-sulfatase	Bones, spine, respiratory	Elosulfase alfa (Vimizim)	2014
MPS VI (Maroteaux-Lamy)	Arylsulfatase B	Bones, eyes, heart, liver	Galsulfase (Naglazyme)	2005
MPS VII (Sly)	Beta-glucuronidase	Bones, liver, spleen	Vestronidase alfa (Mepsevii)	2017
Acid Sphingomyelinase Deficiency (ASMD)	Acid sphingomyelinase	Liver, spleen, lungs	Olipudase alfa (Xenpozyme)	2022
LAL Deficiency (Wolman/CESD)	Lysosomal acid lipase	Liver, cardiovascular system	Sebelipase alfa (Kanuma)	2015

Note: Drug availability and approval status vary by country. Always confirm current FDA approval status and availability with your treating physician or a rare disease specialist.

Benefits of ERT — What Patients Can Realistically Expect

ERT is not a cure, and the degree of benefit varies significantly between patients, diseases, and how early treatment is started. However, clinical evidence across multiple conditions demonstrates consistent and often life-changing benefits:

Gaucher Disease

• Organ size reduction: ERT consistently reduces spleen and liver enlargement (organomegaly), often normalizing organ size within 1–2 years of treatment.
• Blood count improvement: Anemia and thrombocytopenia (low platelet count) typically improve substantially, reducing fatigue and bleeding risk.
• Bone disease: ERT reduces bone pain and bone crises, and can increase bone mineral density over time, reducing fracture risk.
• Energy and quality of life: Most patients report significant improvement in energy levels and ability to participate in normal daily activities.

Fabry Disease

• Pain reduction: Neuropathic pain (burning sensations in the hands and feet) often decreases significantly with ERT.
• Kidney protection: ERT slows the progression of kidney damage, helping preserve kidney function for longer, particularly when started early.
• Cardiac benefit: ERT can reduce left ventricular hypertrophy (heart thickening) and decrease cardiac event risk when started before advanced damage has occurred.

Pompe Disease

• Respiratory improvement: ERT can stabilize or improve respiratory muscle function, reducing dependence on ventilator support in some patients.
• Motor function: Muscle strength and walking ability can improve, particularly in patients treated early. The newer avalglucosidase alfa (Nexviazyme) shows significantly better muscle uptake than older formulations.
• Infant survival: In classic infantile-onset Pompe disease, ERT has transformed a condition that was uniformly fatal in infancy into one where many children survive into childhood and beyond.

Risks and Side Effects of ERT

ERT is generally well tolerated by most patients, but there are several categories of potential adverse effects that patients and caregivers should understand:

Infusion-Related Reactions (IRRs)

The most common side effects of ERT are infusion-related reactions — symptoms that occur during or shortly after the infusion. These include fever, chills, nausea, flushing, headache, chest tightness, and skin rash. IRRs are most common in the first few months of treatment and tend to decrease in frequency and severity over time. They are managed by slowing the infusion rate, administering pre-medications, and in severe cases temporarily stopping the infusion.

Severe anaphylactic reactions are rare but can occur. All ERT infusion centers are equipped to manage anaphylaxis, and nursing staff are trained to recognize and respond to it immediately.

Immune Responses — Antibody Development

Because the manufactured enzyme is a foreign protein, some patients develop anti-drug antibodies (ADAs) — immune responses against the replacement enzyme. This is particularly significant in Pompe disease, where patients who produce no endogenous enzyme at all (CRIM-negative patients) are at high risk of developing high-titer inhibitory antibodies that can completely neutralize ERT’s effectiveness.

Immune tolerance induction protocols — using immunosuppressive drugs before and during early ERT — are now routinely used in high-risk Pompe patients to prevent antibody formation. For other conditions, antibody monitoring is performed regularly to detect immune responses early.

Other Side Effects

• Fatigue: Post-infusion fatigue is commonly reported, typically lasting 24–48 hours. Most patients find it manageable and schedule infusions around their work or school commitments.
• Headache and muscle aches: Mild flu-like symptoms can follow infusions, particularly in the early months of treatment.

Limitations of ERT

Despite its transformative impact, ERT has important limitations that continue to drive research into next-generation therapies:

• Not a cure: ERT does not correct the underlying genetic mutation. Treatment must continue indefinitely — stopping ERT typically results in gradual re-accumulation of substrate and return of symptoms.
• Cannot cross the blood-brain barrier: Standard ERT enzymes are too large to cross from the bloodstream into the brain. This is a critical limitation for diseases where neurological involvement is significant — such as MPS II (Hunter syndrome) and Gaucher disease type 3 — because ERT cannot treat or prevent brain damage in these conditions.
• Variable efficacy: ERT works best when started early, before significant irreversible organ damage has occurred. Patients with advanced disease at the time of diagnosis may see less benefit. The degree of response also varies between individuals with the same condition.
• Lifelong commitment: Biweekly infusions — typically lasting 2–4 hours each — represent a significant time commitment over a lifetime. For many patients, this affects work schedules, travel, and quality of life in ways that go beyond the disease itself.
• Immune responses: As described above, antibody formation can reduce treatment effectiveness in some patients, requiring additional immunosuppressive management.

ERT Cost in the United States — What Families Need to Know

These costs are comparable to other advanced diagnostics, similar to MRI cost in the US.

ERT drugs are among the most expensive medications in the world. Understanding the cost landscape is critical for patients and families navigating treatment access.

ERT Drug	Condition	Estimated Annual Cost (US)
Imiglucerase (Cerezyme)	Gaucher Disease	$100,000 – $400,000
Agalsidase beta (Fabrazyme)	Fabry Disease	$200,000 – $300,000
Alglucosidase alfa (Myozyme)	Pompe Disease (infantile)	$300,000 – $900,000+
Avalglucosidase alfa (Nexviazyme)	Pompe Disease	$250,000 – $600,000
Laronidase (Aldurazyme)	MPS I	$200,000 – $500,000
Idursulfase (Elaprase)	MPS II	$300,000 – $700,000
Elosulfase alfa (Vimizim)	MPS IVA	$350,000 – $900,000

How Do Patients Afford ERT?

• Private insurance: Most major US health insurers cover FDA-approved ERT for confirmed diagnoses, as these are life-sustaining treatments with no alternatives. Prior authorization is required. Coverage denials do occur and can be appealed.
• Medicare and Medicaid: Both programs cover ERT when medically necessary. Medicaid coverage is particularly important for pediatric patients and low-income families.
• Manufacturer patient assistance programs: All ERT manufacturers — Sanofi Genzyme, Takeda, BioMarin, Ultragenyx, and others — operate patient assistance programs that provide free or heavily discounted medication for eligible uninsured or underinsured patients.
• Rare disease advocacy organizations: Organizations such as the National Gaucher Foundation, Fabry Support and Information Group, Acid Maltase Deficiency Association (AMDA), and MPS Society offer financial assistance navigation and advocacy support.
• State pharmaceutical assistance programs: Some US states have programs specifically designed to assist patients with rare disease medication costs.

Practical tip: Ask your treating physician to refer you to a patient services coordinator at the ERT manufacturer. These coordinators specialize in insurance navigation and can often resolve prior authorization issues or connect patients with financial assistance faster than navigating the system independently.

ERT vs Gene Therapy — What Is the Difference?

Gene therapy represents the next frontier in treating lysosomal storage diseases — and understanding how it differs from ERT helps patients assess their future treatment options.

Feature	ERT	Gene Therapy
Mechanism	Delivers replacement enzyme via IV infusion	Corrects the genetic mutation causing enzyme deficiency
Frequency	Every 1–2 weeks, lifelong	Potentially one-time or infrequent treatment
Curative potential	No — manages symptoms only	Potentially curative — addresses root cause
Blood-brain barrier	Cannot cross	Some vectors can reach the brain
Current status	FDA-approved for multiple conditions	Clinical trials ongoing; some approvals emerging
Cost	$100K–$900K/year ongoing	One-time cost potentially $1M–$3M+
Availability	Widely available through infusion centers	Limited — trial or specialized centers only

Gene therapy for lysosomal storage diseases is advancing rapidly. Clinical trials are ongoing for Gaucher disease, Pompe disease, Fabry disease, and several MPS conditions. The FDA granted Breakthrough Therapy designation to several gene therapy candidates in recent years, accelerating their development. However, gene therapy is not yet a replacement for ERT for most patients — it remains largely experimental outside of specific approved indications.

How Is a Lysosomal Storage Disease Diagnosed?

Because LSDs are rare and their symptoms often overlap with more common conditions, diagnosis is frequently delayed by months to years. Understanding the diagnostic pathway helps patients advocate for timely evaluation.

1. Newborn screening: Many US states now include several LSDs (Pompe, Fabry, Gaucher, MPS I, MPS II) in their standard newborn screening panels, allowing treatment to begin before symptoms develop.
2. Enzyme activity assay: A blood test measuring the activity level of the specific enzyme in question, often performed using enzyme activity blood tests.. Very low or absent activity confirms the diagnosis.
3. Genetic testing: DNA sequencing identifies the specific mutation(s) causing the enzyme deficiency, confirms diagnosis, guides prognosis, and enables family screening.
4. Biomarker testing: Certain substrate levels (such as lyso-Gb3 in Fabry disease or glucosylsphingosine in Gaucher disease) serve as disease activity markers and are monitored during treatment.
5. Referral to a metabolic disease specialist or lysosomal disease specialist: These conditions require management by physicians with specific expertise in metabolic diseases — typically found at academic medical centers and rare disease specialty clinics.

Frequently Asked Questions About ERT

Is ERT a cure for lysosomal storage diseases?

No — ERT is not a cure. It manages symptoms and slows disease progression by continuously supplying the missing enzyme, but it does not correct the underlying genetic mutation. Patients must continue receiving infusions indefinitely. If ERT is stopped, substrate re-accumulates and symptoms typically return over months to years. Gene therapy research is advancing toward potential curative treatments for several LSDs, but these are not yet widely available.

How long does it take to see results from ERT?

The timeline varies by condition and individual patient. In Gaucher disease, blood count improvements (anemia, platelet counts) are often noticeable within 3–6 months of starting ERT. Organ size reduction (spleen and liver) typically takes 12–24 months. Bone disease improvement requires years of consistent treatment. In Pompe disease, respiratory and motor function improvements can be seen within 6–12 months. Patients are monitored with regular lab tests, imaging, and functional assessments to track treatment response.

Can ERT be given to newborns and infants?

Yes — ERT is approved for and given to newborns and infants for several conditions, most notably classic infantile-onset Pompe disease, where early treatment before the onset of severe muscle and heart damage is critical for survival. Newborn screening programs in many US states now identify affected infants at birth, enabling treatment to begin within the first weeks of life. Early treatment consistently produces better outcomes than treatment started after symptom onset.

What happens if ERT infusions are missed or delayed?

Missing occasional infusions is generally tolerated without immediate consequences, but consistent delays or gaps in treatment allow substrate to re-accumulate and symptoms to worsen. Patients who miss multiple infusions may also be at increased risk of developing infusion-related reactions when they restart treatment, as the immune system may respond more aggressively after a gap. Patients who need to temporarily stop ERT for any reason should discuss the plan with their treating physician.

Are there any foods or activities to avoid during ERT treatment?

There are no universal dietary restrictions associated with ERT. However, patients are typically advised to avoid strenuous physical activity on the day of infusion and to stay well hydrated. Specific dietary guidance varies by condition — for example, Gaucher disease patients may receive advice about bone health nutrition (adequate calcium and vitamin D). Always follow the specific recommendations of your metabolic disease specialist.

Is ERT available outside the United States?

Most FDA-approved ERT drugs are also approved by the European Medicines Agency (EMA) and are available in Europe, Canada, Australia, and Japan. Availability in lower-income countries is more limited due to cost barriers, though manufacturer compassionate use and access programs exist for some conditions. International patient advocacy organizations can help families in underserved regions navigate access.

Key Takeaways

• Enzyme Replacement Therapy delivers laboratory-manufactured enzymes via IV infusion to treat lysosomal storage diseases — rare genetic conditions where a specific enzyme is missing or deficient.
• ERT is FDA-approved for Gaucher, Fabry, Pompe, MPS I, MPS II, MPS IVA, MPS VI, MPS VII, ASMD, and LAL deficiency. Multiple approved drugs exist for some conditions.
• ERT is not a cure — it manages symptoms and slows progression but requires lifelong biweekly infusions. Stopping treatment leads to disease re-accumulation.
• ERT cannot cross the blood-brain barrier, limiting its effectiveness for neurological manifestations of some LSDs — a key driver of ongoing gene therapy research.
• ERT drugs cost $100,000 to over $900,000 per year in the US. Most insurers cover ERT with prior authorization. Manufacturer patient assistance programs provide support for uninsured and underinsured patients.
• Gene therapy offers the potential for curative treatment and is in active clinical trials for several LSDs, but is not yet a replacement for ERT for most patients.
• Early diagnosis and early treatment consistently produce better outcomes — newborn screening programs that identify LSDs at birth represent the most significant advance in improving long-term prognosis.

Sources and Further Reading

• National Gaucher Foundation: gaucherdisease.org
• Fabry Support and Information Group: fabry.org
• Acid Maltase Deficiency Association (Pompe disease): amda-pompe.org
• MPS Society: mpssociety.org
• NIH Genetic and Rare Diseases Information Center: rarediseases.info.nih.gov
• FDA Rare Disease Program: fda.gov/patients/rare-diseases-fda
• Orphanet Rare Disease Encyclopedia: orpha.ne

About this article:

Prepared by the LabCare Editorial Team, drawing on 14+ years of experience in the diagnostic laboratory industry. All health content is reviewed for factual accuracy before publication. Always consult a qualified healthcare professional or rare disease specialist for medical decisions.

Disclaimer: This article is for educational and informational purposes only and does not constitute medical advice. Enzyme Replacement Therapy is a specialized medical treatment managed by rare disease physicians. Diagnosis, treatment decisions, and insurance navigation for lysosomal storage diseases should always involve qualified medical specialists. Drug availability, pricing, and approval status are subject to change.